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Functional loss of both alleles of the breast cancer susceptibility gene, BRCA2, facilitates tumorigenesis. However, 
the direct effects of BRCA2 heterozygosity remain unclear. Here, BRCA2 heterozygosity was mimicked in HT-29 
colon cells by reducing levels of BRCA2 through stable RNA interference. No difference in RAD51 subcellular 
localization and focus formation was observed between control and mimicked heterozygous cell lines. DNA 
repair ability, as measured by colony survival following mitomycin C treatment and ultraviolet radiation 
e x p o s u r e ,  w a s  a l s o  u n a f f e c t e d  b y  r e d u c e d  l e v e l s  o f  B R C A 2 .  I n t e r e s t i n g l y ,  t h e  g r o w t h  r a t e  o f  t h e  m i m i c k e d  
BRCA2 heterozygous cell line was significantly lower than that of control cells. Increased expression of p53 in the 
mimicked heterozygous cells was observed, perhaps in response to BRCA2 deficiency. Levels of p27 were also 
found to be slightly increased in cells with reduced BRCA2, perhaps contributing to the slower growth rate. 
Overall, these results suggest that tumors are unlikely to arise directly from BRCA2 heterozygous cells without 
other genetic events such as loss of the wild-type BRCA2 allele and/or loss of p53 function or other cell cycle 
inhibitors. 
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1.  INTRODUCTION 
  The majority of inherited breast and ovarian 
cancers are caused by germline mutations of the 
BRCA1 and BRCA2 genes [1]. In addition, BRCA2 
mutations have been associated with a number of 
other tumor types, including colon cancer [2, 3]. Loss 
of wild-type function of both BRCA2 alleles allows 
tumors to proliferate in affected individuals, 
classifying BRCA2 as a tumor suppressor gene [4]. The 
human BRCA2 gene encodes a nuclear protein of 3,418 
amino acids [5], and is believed to play a pivotal role in 
DNA damage repair [6]. The BRCA2 protein has been 
shown to bind to RAD51, the mammalian homolog of 
the RecA recombinase [6-9], and thus is believed to be 
involved in the repair of DNA double-strand breaks 
[6]. In support of this notion, cells lacking a functional 
BRCA2 gene show hypersensitivity to DNA damaging 
agents such as mitomycin C (MMC) and sensitivity to 
chemicals such as methyl methane sulfonate [10]. In 
addition, cells with homozygous truncations in BRCA2 
are genetically unstable [8, 9, 11] and are lacking in 
homology-directed DNA repair of chromosomal 
breaks [12, 13]. Moreover, BRCA2 regulates both the 
DNA binding ability of RAD51 and its intracellular 
location [14].  
  The effect of heterozygosity of the BRCA2 gene 
on human cells remains unclear. According to 
Knudson’s two hit hypothesis for tumor suppressor 
genes [15], loss of both alleles must occur prior to 
tumor growth. However, it may be possible that tumor 
growth can be initiated in heterozygous cells prior to 
loss of the second, wild-type allele. In support of this 
hypothesis, heterozygosity for a BRCA2 mutation has 
been shown to cause sensitivity to DNA damage 
agents and reduced RAD51 focus formation after 
irradiation in the chicken B cell line DT40 [16]. 
Additionally, chromosomal rearrangements, increased 
rates of sister chromatid exchanges and double strand 
breaks have been observed in cells from heterozygous 
mutation carriers of BRCA2 [17, 18]. In this report, we 
have utilized HT-29 colon cancer cells and have 
mimicked the heterozygous state of BRCA2 in these 
cells through RNA interference. The characterization 
of the resulting cells with regard to key cellular BRCA2 
functions is presented here.  
 
2.  MATERIALS AND METHODS  
Retroviral vectors 
For short hairpin RNA (shRNA) targeting of 
BRCA2, the pRETRO-SUPER plasmid [19] was utilized 
as previously described [20]. Pairs of oligonucleotides 
against BRCA2 base sequences 115-133 and 216-234 
were separately annealed and ligated into 
BglII/HindIII sites in pRETRO-SUPER as described 
[20]. Targeting of luciferase using the pRETRO-SUPER 
shRNA plasmid was also as described [20]. All 
plasmids were confirmed by DNA sequencing and/or 
restriction digestion. Int. J. Biol. Sci. 2007, 3 
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Cell culture and retroviral infection 
HT-29 cells were grown in Dulbecco’s 
Modification of Eagle’s Medium (DMEM) containing 
Penicillin/Streptomycin (100 units/ml and 10μg/ml, 
respectively) and 10% Serum Supreme (Bio Whitaker). 
Retroviral supernatants were produced using 293T 
cells and cotransfection with the packaging plasmid 
pCL-Ampho [21], as previously described [20]. To 
achieve lower BRCA2 levels, retroviral supernatants 
directing expression of shRNA directed at both bases 
115-133 and 216-234 of BRCA2 were mixed together 
1:1, supplemented with 10 μg/ml polybrene, and 
incubated with HT-29 cells overnight (hereafter called 
BRCA2 RNAi cells). HT-29 cells were similarly 
infected with empty vector control retrovirus 
(hereafter called control RNAi cells). Forty-eight hours 
later, infected HT-29 cells were passaged into media 
containing 1µg/ml puromycin for selection. The cells 
were passaged and continued to undergo selection for 
approximately fourteen days.  
Western blotting 
For all western blots, cells in 100mm plates were 
rinsed with PBS and 500µl of lysis buffer [50 mM 
HEPES [pH 7.6], 250 mM NaCl, 0.1% NP-40, 5 mM 
EDTA, 1 mM PMSF, 2 µg each of aprotinin, bestatin, 
and leupeptin/ml] was added to plates and incubated 
for 30 minutes at 4°C. Cells were then collected using a 
plastic cell scraper and resuspended by pipetting. The 
lysates were clarified by microcentrifugation for 15 
minutes at 4°C. The supernatants were collected and a 
Bradford assay (Bio-Rad) was conducted to determine 
protein concentration. 25µg of lysates for each cell line 
were separated on an SDS-PAGE gel. The gel was then 
transferred to a PVDF membrane and subjected to 
western blotting. Quantification of band intensities 
was performed using the gel analyzer function of 
Image J (version 1.34S). 
Subcellular Fractionation 
HT-29 cell lines grown to confluence in 100mm 
plates were trypsinized and collected with fresh media 
i n  1 4 m l  t u b e s ,  w a s h e d  w i t h  P B S ,  a n d  r e c o l l e c t e d  i n  
1.5ml eppendorf tubes. 500µl of homogenization buffer 
[250mM sucrose, 10mM Tris (pH 7.5), 10mM KCl, 
1.5mM MgCl2, 1mM PMSF, 1µl/ml of aprotinin, 
1µl/ml of bestatin, 1µl/ml of leupeptin, and 1mM 
Na2VO3 was added to each tube and mixed. Tubes 
were then placed on ice for twenty minutes and mixed 
every four to five minutes. Cells were collected at the 
bottom of the tubes and homogenized at the bottom 
using a plastic pestle. The eppendorf tubes were then 
spun at 4°C for ten minutes at 600 x g. The supernatant 
containing the cytosolic fraction was collected. 500µl of 
lysis buffer was added to the pellets (nuclei) in the 
original tube set. The tubes were then placed on ice for 
fifteen minutes, mixed every four to five minutes. The 
tubes were then spun down at 4°C for 15 minutes at 
13,500 rpm in a refrigerated microcentrifuge. The 
supernatant containing the nuclear fraction was 
collected.  
RAD51 focus assay 
Two days prior to immunofluorescence 
microscopy, cells were passaged onto coverslips in a 
six-well plate. The following day, one set of cells was 
treated with 400ng/ml of MMC overnight. The next 
day, cells were fixed with 3.7% paraformaldehyde, 
permeablized with 0.5% Triton X-100, and blocked 
with 0.1% Goat Serum in PBS-Tween. Cells were then 
incubated with primary antibody (rabbit polyclonal 
anti-RAD51, Oncogene Sciences) and secondary 
antibody (Texas-Red conjugated anti-rabbit lgG) as 
directed by manufacturer, washed six times with 
PBS-Tween, stained with 
4'-6-Diamidino-2-phenylindole (DAPI), and mounted 
on microscope slides. Cells were visualized on a Zeiss 
Axioskop fluorescence microscope.  
Clonogenic survival assays 
One day prior to treatment, cells were passaged 
into four 60mm culture plates and incubated until they 
reached fifty percent confluence. For MMC treatment, 
cells were incubated for one hour in media containing 
either 0 ng/ml, 200 ng/ml, 400 ng/ml or 800 ng/ml of 
MMC. Media was then removed and fresh media was 
added to each plate. The next day, the cells were 
resuspended and counted by hemacytometer. 1000 
cells from each plate were added to new plates in 
triplicate. Fresh media was added to the plates every 
two to three days. After two weeks, the cells were fixed 
with 10% acetic acid/10% methanol for 10 minutes and 
stained with 1% crystal violet in methanol for 10 
minutes. The cells were rinsed twice with water, dried, 
and the colonies on the plates were counted. 
Ultraviolet radiation DNA damage assay was 
performed as for MMC assay, except media from 
plates was removed and cells were struck with 
ultraviolet radiation from a germicidal lamp in the 
tissue culture hood at doses of 25 J/m2, 50 J/m2 and 
100 J/m2. 
Standard growth assay 
Cells at approximately fifty percent confluence 
were trypsinized, resuspended in fresh media, and 
counted by hemacytometer. 30,000 cells from each 
plate were added to eighteen 60mm culture plates. 
Fresh media was added to the plates every three days. 
Cells were trypsinized and counted by hemocytometer 
(in triplicate for each cell line) at approximate 3 day 
intervals for up to 19 days. Cells approached 
confluency between days 12 and 15 of growth, 
approximately.  
3.  RESULTS  
 The heterozygous state of BRCA2 was mimicked 
in HT-29 colon cells via RNA interference in order to 
determine possible functional effects. BRCA2 RNAi 
cells were created via overnight incubation with 2 
retroviruses containing shRNA BRCA2 targeting 
constructs (targeting BRCA2 bases 115-133 and 
216-234) mixed together, as described in Materials and 
Methods. A control line of HT-29 cells was created 
with a control RNAi retrovirus, as also described. Int. J. Biol. Sci. 2007, 3 
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Following a 14 day selection, cells at fifty percent 
confluence were lysed and quantified for BRCA2 
protein expression level by western blot to verify a 
reduction of BRCA2 protein levels to those likely to be 
seen with BRCA2 heterozygosity. In comparison to the 
parental and control RNAi cell lines, the BRCA2 RNAi 
cells expressed BRCA2 protein levels that were 
approximately half of the parental and control cells, 
verifying the mimic of BRCA2 heterozygosity (Figure 
1a). The lower expression was not due to a non-specific 
effect of the shRNA since no reduction in BRCA2 was 
seen using a retroviral construct coding for a shRNA 




Figure 1. BRCA2 heterozygosity mimicked through RNA 
interference in HT-29 colon cells. (A) 25µg of lysates from 
parental, BRCA2 RNAi, and control RNAi cells were loaded on 
a SDS-10% polyacrylamide gel and a BRCA2 western blot was 
performed (top panel). Quantification of BRCA2 band 
intensities as a percent of the parental band is indicated. A 
non-specific band was utilized as a loading control in the 
experiment (middle panel). A lighter exposure of the 
non-specific band is shown (lower panel). (B) Western blot was 
performed as in (A), except lysates from parental HT-29 cells 
were compared to HT-29 cells stably infected with a shRNA 
construct targeting luciferase (Luc RNAi). 
 
 To determine whether the mimicked 
heterozygous state of BRCA2 altered the normal 
cellular activities of the BRCA2 protein, we examined 
aspects of the BRCA2 functional interaction with 
RAD51. Crude subcellular fractionation was 
conducted to determine whether reduced BRCA2 
levels altered the cellular localization of RAD51. Cell 
lines were fractionated into nuclear and cytosolic 
fractions and analyzed by RAD51 Western blotting. 
There was no significant difference between the 
control RNAi and BRCA2 RNAi cell lines in either the 
nuclear or cytosolic levels of RAD51 (Figure 2a).  
 
 
Figure 2. No effect of mimicked BRCA2 heterozygosity on 
RAD51 localization and foci formation. (A) Subcellular 
fractionation was conducted to separate nuclear fraction from 
cytosolic fraction. 25µg of each fraction was loaded on a 
SDS-10% polyacrylamide gel and a RAD51 western blot was 
performed. Poly (ADP-ribose) polymerase (PARP) was utilized 
as a control for the fractionation. N = nuclear fraction, C = 
cytosolic fraction. (B) Cell lines were grown on coverslips and 
treated with 400ng/ml of MMC overnight and RAD51 
immunostaining was performed. RAD51 foci are seen as red 
sharp, punctuate staining in left panels; DAPI labeled nuclei are 
shown in blue in right panels. No RAD51 foci were seen with 
untreated cells (data not shown).  
 
To further determine whether mimicked BRCA2 
heterozygosity affected the BRCA2-RAD51 interaction, 
a RAD51 focus assay was conducted. BRCA2-null cells 
have been previously shown to be deficient in the 
formation of RAD51 foci [22]. However, no significant 
difference between the RAD51 foci of both the BRCA2 
RNAi and control RNAi cells was observed (Figure Int. J. Biol. Sci. 2007, 3 
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2a). Both cell lines had a similar abundance of RAD51 
foci within the nuclei and there was no apparent 
difference between the sizes of the RAD51 foci seen in 
both cell lines (Figure 2b). Thus, reducing BRCA2 
levels does not seem to affect this BRCA2 function.  
  We next assayed whether the mimicked 
heterozygous state of BRCA2 has an effect on DNA 
damage repair. Since cells lacking the BRCA2 gene 
have shown hypersensitivity to MMC and UV, these 
treatments were utilized as damaging agents and DNA 
repair was assessed by clonogenic survival assays. No 
significant difference in clonogenic survival was 
observed with either the higher doses (400ng/ml and 
800ng/ml) of MMC treatment (Figure 3a) or with UV 
treatment (Figure 3b). Thus, the mimicked 
heterozygous state of BRCA2 did not alter colony 
survival in response to either MMC and UV. However, 
in both DNA damage assays, there was a significantly 
greater number of control RNAi colonies than BRCA2 
RNAi from the untreated cells at the end of the 
two-week assay, despite equal plating. Representative 
plates of colonies from the untreated cells of the UV 
survival assay are shown (Figure 3c). The amount of 
BRCA2 RNAi colonies was 50.9% (±13.2%) of the 
control colonies in the MMC survival assay (p < 0.002) 
and 46.1% (±7.8%) of the control colonies in the UV 
survival assay (p < 0.008).  
The augmented amount of colonies in the control 
RNAi line suggested that the growth of BRCA2 RNAi 
cells might be inhibited, a possible effect of the 
mimicked heterozygous state of BRCA2. To test this 
hypothesis, a standard growth assay was performed 
and differences between the cell lines were observed. 
A graphical representation of the standard growth of 
the BRCA2 RNAi and control RNAi cells is shown 
(Figure 4a). BRCA2 RNAi cells were observed to have 
a significantly decreased standard growth rate at all 
time points except the earliest (3 days), including time 
points prior to when the cells approached confluency, 
suggesting that the observed growth deficiency is 
intrinsic to the BRCA2 RNAi cells. In contrast, no 
difference in growth was seen between parental and 
luciferase RNAi cells (Figure 4b).   
We then investigated the basis of the observed 
decreased growth rate. To see if a compensatory 
increase in BRCA1 might cause slower growth in 
BRCA2 RNAi cells, a BRCA1 Western blot was 
performed (Figure 4c, top panel). There was no 
observable difference of the BRCA1 levels among the 
parental, control RNAi, and BRCA2 RNAi cell lines. 
Because levels of p53 have been previously shown to 
increase due to loss of BRCA2 [23], a p53 Western blot 
was performed (Figure 4c, second panel). An 
observable increase in p53 was present in the BRCA2 
RNAi cells as compared to the parental and control 
RNAi cell lines. However, since HT-29 cells express a 
mutant p53, it is very possible that the increased p53 
levels in BRCA2 cells do not have any functional 
consequence. In support of this notion, the p53 target 
protein, p21, was not detectable in these cells (data not 
shown), suggesting that the slower growth of BRCA2 
RNAi cells may occur through mechanisms other than 
p53-mediated growth arrest. Along these lines, a 
p27kip1 western was performed and levels of p27kip1 
were found to be slightly increased in BRCA2 RNAi 
cells (Figure 4c, fourth panel). 
 
 
Figure 3. No significant difference in survival after MMC 
DNA damage for BRCA2 RNAi and control RNAi HT-29 
cells. (A) 1000 cells were plated in triplicate after treatment with 
0 ng/ml, 200 ng/ml, 400 ng/ml, and 800 ng/ml of MMC in media 
and colonies were counted after two weeks of growth. No 
significant difference in DNA repair ability was observed at 
400ng/ml and 800 ng/ml doses of MMC treatment (*p < 0.05, 
**p > 0.08, ***p > 0.40, Student's paired, two-tailed t-test). (B) 




2 and 100 J/m
2 and colonies were counted after two 
weeks. No significant difference in DNA repair ability was 
observed as a result of UV radiation (*p > 0.05, **p > 0.50, 
***p > 0.90, Student's paired, two-tailed t-test). (C) Colonies of 
untreated (0 J/m
2 UV dose)
 control and BRCA2 RNAi cells 
from the UV colony survival assay in (B) are shown to 
demonstrate the intrinsic colony forming deficiency of BRCA2 
RNAi cells. 




Figure 4. BRCA2 RNAi cells demonstrate inhibited growth. 
(A)  A standard growth assay was performed on control and 
BRCA2 RNAi cells. 30,000 cells for each cell line were plated 
on 18 60-mm plates. Three plates of cells for each cell line were 
counted at each time point over the course of a nineteen-day 
period and graphed in a logarithmic scale. Time points 
demonstrating statistically significant differences between cell 
lines (p < 0.05, Student's paired, two-tailed t-test) are noted by 
asterisk. (B) A standard growth assay was performed as in (A) 
comparing parental HT-29 cells and cells stably infected with a 
shRNA construct targeting luciferase (Luc RNAi). (C) 25µg of 
cell lysates were loaded on a SDS-10% polyacrylamide gel and 
BRCA1, p53, p27 western blotting was performed. Alpha 
tubulin western blotting (lower middle panel) served as a control 
for equal loading of lysates.  
4.  DISCUSSION  
Mimicked BRCA2 heterozygosity did not appear 
to alter the normal cellular functions of BRCA2 in 
HT-29 colon cells. No significant difference in either 
RAD51 localization or RAD51 focus formation was 
seen between the BRCA2 RNAi cell line and the 
control RNAi cell line, in contrast to BRCA2-deficient 
Capan-1 cells, which demonstrate decreased RAD51 
focus formation [22]. Furthermore, lower BRCA2 
levels did not seem to alter the DNA repair ability of 
HT-29 colon cells, with percent survival rates similar to 
control cells following MMC or UV treatment. Overall, 
these results indicate that it is unlikely that 
tumorigenesis occurs prior to loss of both BRCA2 
alleles. The findings in this report are not in agreement 
with the reduced RAD51 focus formation after 
irradiation and sensitivity to DNA damage agents 
observed in a chicken B cell line, DT40, that was 
heterozygous for BRCA2 [16]. A possible explanation 
for these differences may be due to effects of the 
mutant allele in the DT40 cell line, which produces a 
truncated BRCA2 protein that is not present in the 
mimicked heterozygous cells.  
The clearest effect of mimicked BRCA2 
heterozygozity that was observed was a diminished 
rate of growth. There were no observable differences in 
the levels of BRCA1 protein in mimicked BRCA2 
heterozygous cells, suggesting a lack of compensatory 
action of the BRCA1 and BRCA2 tumor suppressor 
genes. In contrast, a detectable increase in the levels of 
p53 was observed in the BRCA2 RNAi cell line. 
However, it is uncertain whether this p53 increase 
contributed to the observed reduced cell growth rate of 
BRCA2 RNAi cells since p53 is mutated in the HT-29 
cell line. Furthermore, p21 levels were not observed to 
be increased concomitantly, suggesting that the p53 
increase may have no functional significance with 
respect to the cell cycle. It is not certain whether 
non-transcriptional activities of p53 are also lost 
through this same mutation, and whether they may be 
partly responsible for the observed growth differences. 
Levels of p27kip1 were also slightly increased in BRCA2 
RNAi cells, perhaps contributing to their growth 
deficiency. However, it is also possible that the 
observed increases in p53 and p27kip1 are merely 
cellular responses to other defects resulting from 
decreased BRCA2 levels (such as subtle defects in 
DNA repair that are not detectable by the assays 
employed here) that may have a more direct impact on 
cell division and cell growth rates. 
The increased p53 that was observed in HT-29 
cells as a result of mimicked BRCA2 heterozygosity is 
likely to also occur in cells with intact p53, where it 
may have more of a tumor suppressing role. Mouse 
embryonic fibroblasts that are homozygous for BRCA2 
knockout alleles have been shown to have a defect in 
proliferation caused by the over-expression of p53 [23]. 
These results suggested that the loss of the p53 
checkpoint may be vital for tumor progression 
generated by mutations in BRCA2. Loss of p53 has 
been suggested to be necessary for breast tumor Int. J. Biol. Sci. 2007, 3 
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formation following BRCA2 loss [24]. In this study, the 
increased levels of p53 in the BRCA2 RNAi cells may 
explain the infrequent incidences of colon cancer in 
BRCA2 carriers. It is probable that the same 
mechanisms may function in BRCA2 heterozygotes in 
vivo, with increased p53 levels preventing the 
proliferation of malignant tumors in the human colon 
and perhaps in other tissues as well. However, it is also 
possible that the effects of lower BRCA2 levels may 
differ depending on cell type. Investigations into the 
differential effects of BRCA2 levels on cell growth and 
p53 activation may provide insight into why BRCA2 
mutations lead to a small subset of observed tumor 
types.  
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